Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Differential effects of natural Curcumin and chemically modified curcumin on inflammation and bone resorption in model of experimental periodontitis.

Curylofo-Zotti FA, Elburki MS, Oliveira PA, Cerri PS, Santos LA, Lee HM, Johnson F, Golub LM, Rossa C Junior, Guimarães-Stabili MR.

Arch Oral Biol. 2018 Apr 10;91:42-50. doi: 10.1016/j.archoralbio.2018.04.007. [Epub ahead of print]

PMID:
29669267
2.

A Chemically Modified Curcumin (CMC 2.24) Inhibits Nuclear Factor κB Activation and Inflammatory Bone Loss in Murine Models of LPS-Induced Experimental Periodontitis and Diabetes-Associated Natural Periodontitis.

Elburki MS, Rossa C Jr, Guimarães-Stabili MR, Lee HM, Curylofo-Zotti FA, Johnson F, Golub LM.

Inflammation. 2017 Aug;40(4):1436-1449. doi: 10.1007/s10753-017-0587-4.

PMID:
28534138
3.

A Novel Chemically Modified Curcumin "Normalizes" Wound-Healing in Rats with Experimentally Induced Type I Diabetes: Initial Studies.

Zhang Y, McClain SA, Lee HM, Elburki MS, Yu H, Gu Y, Zhang Y, Wolff M, Johnson F, Golub LM.

J Diabetes Res. 2016;2016:5782904. doi: 10.1155/2016/5782904. Epub 2016 Apr 13.

4.

A novel chemically modified curcumin reduces inflammation-mediated connective tissue breakdown in a rat model of diabetes: periodontal and systemic effects.

Elburki MS, Moore DD, Terezakis NG, Zhang Y, Lee HM, Johnson F, Golub LM.

J Periodontal Res. 2017 Apr;52(2):186-200. doi: 10.1111/jre.12381. Epub 2016 Apr 1.

PMID:
27038334
5.

Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases.

Golub LM, Elburki MS, Walker C, Ryan M, Sorsa T, Tenenbaum H, Goldberg M, Wolff M, Gu Y.

Int Dent J. 2016 Jun;66(3):127-35. doi: 10.1111/idj.12221. Epub 2016 Mar 23. Review.

PMID:
27009489
6.

DIFFERENTIAL SUSCEPTIBILITY OF HUMAN SP-B GENETIC VARIANTS ON LUNG INJURY CAUSED BY BACTERIAL PNEUMONIA AND THE EFFECT OF A CHEMICALLY MODIFIED CURCUMIN.

Xu Y, Ge L, Abdel-Razek O, Jain S, Liu Z, Hong Y, Nieman G, Johnson F, Golub LM, Cooney RN, Wang G.

Shock. 2016 Apr;45(4):375-84. doi: 10.1097/SHK.0000000000000535.

7.

The Use of Doxycycline and Tetracycline in Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Colonization.

Lauhio A, Tervahartiala T, Leppilahti J, Golub LM, Ryan ME, Sorsa T.

Clin Infect Dis. 2015 Sep 15;61(6):1031. doi: 10.1093/cid/civ502. Epub 2015 Jul 18. No abstract available.

PMID:
26188207
8.

The Link Between Periodontitis and Rheumatoid Arthritis: A Periodontist's Perspective.

Payne JB, Golub LM, Thiele GM, Mikuls TR.

Curr Oral Health Rep. 2015;2:20-29. Review.

9.

A novel chemically modified curcumin reduces severity of experimental periodontal disease in rats: initial observations.

Elburki MS, Rossa C, Guimaraes MR, Goodenough M, Lee HM, Curylofo FA, Zhang Y, Johnson F, Golub LM.

Mediators Inflamm. 2014;2014:959471. doi: 10.1155/2014/959471. Epub 2014 Jun 29.

10.

4-methoxycarbonyl curcumin: a unique inhibitor of both inflammatory mediators and periodontal inflammation.

Gu Y, Lee HM, Napolitano N, Clemens M, Zhang Y, Sorsa T, Zhang Y, Johnson F, Golub LM.

Mediators Inflamm. 2013;2013:329740. doi: 10.1155/2013/329740. Epub 2013 Dec 24.

11.

Inhibition of anthrax lethal factor by curcumin and chemically modified curcumin derivatives.

Antonelli AC, Zhang Y, Golub LM, Johnson F, Simon SR.

J Enzyme Inhib Med Chem. 2014 Oct;29(5):663-9. doi: 10.3109/14756366.2013.837901. Epub 2013 Oct 9.

12.

Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24.

Botchkina GI, Zuniga ES, Rowehl RH, Park R, Bhalla R, Bialkowska AB, Johnson F, Golub LM, Zhang Y, Ojima I, Shroyer KR.

PLoS One. 2013 Sep 24;8(9):e69884. doi: 10.1371/journal.pone.0069884. eCollection 2013.

13.

Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages.

Salminen A, Pussinen PJ, Payne JB, Stoner JA, Jauhiainen M, Golub LM, Lee HM, Thompson DM, Sorsa T.

Inflamm Res. 2013 Jul;62(7):711-20. doi: 10.1007/s00011-013-0626-z. Epub 2013 May 7.

14.

The association between clinical and radiographic periodontitis measurements during periodontal maintenance.

Payne JB, Nummikoski PV, Thompson DM, Golub LM, Stoner JA.

J Periodontol. 2013 Oct;84(10):1382-90. doi: 10.1902/jop.2012.120484. Epub 2012 Dec 3.

15.

Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine.

Gu Y, Walker C, Ryan ME, Payne JB, Golub LM.

J Oral Microbiol. 2012;4. doi: 10.3402/jom.v4i0.19227. Epub 2012 Oct 12.

16.

pKa, zinc- and serum albumin-binding of curcumin and two novel biologically-active chemically-modified curcumins.

Zhang Y, Golub LM, Johnson F, Wishnia A.

Curr Med Chem. 2012;19(25):4367-75.

PMID:
22830351
17.

Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins.

Zhang Y, Gu Y, Lee HM, Hambardjieva E, Vranková K, Golub LM, Johnson F.

Curr Med Chem. 2012;19(25):4348-58.

PMID:
22830350
18.

Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation.

Gu Y, Lee HM, Sorsa T, Salminen A, Ryan ME, Slepian MJ, Golub LM.

Pharmacol Res. 2011 Dec;64(6):573-9. doi: 10.1016/j.phrs.2011.06.023. Epub 2011 Jul 13. Review.

PMID:
21771657
19.

Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS).

Roy SK, Kendrick D, Sadowitz BD, Gatto L, Snyder K, Satalin JM, Golub LM, Nieman G.

Pharmacol Res. 2011 Dec;64(6):580-9. doi: 10.1016/j.phrs.2011.06.012. Epub 2011 Jun 21. Review.

20.

Clinical applications of non-antibacterial tetracyclines. Part II.

Golub LM, Greenwald RA.

Pharmacol Res. 2011 Dec;64(6):549-50. doi: 10.1016/j.phrs.2011.06.004. Epub 2011 Jun 13. No abstract available.

PMID:
21712090
21.

Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase.

Gu Y, Lee HM, Simon SR, Golub LM.

Pharmacol Res. 2011 Dec;64(6):595-601. doi: 10.1016/j.phrs.2011.05.011. Epub 2011 May 31. Review.

PMID:
21651982
22.

Serum bone biomarkers and oral/systemic bone loss in humans.

Payne JB, Stoner JA, Lee HM, Nummikoski PV, Reinhardt RA, Golub LM.

J Dent Res. 2011 Jun;90(6):747-51. doi: 10.1177/0022034511402993. Epub 2011 Mar 21.

23.
24.

Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic.

Payne JB, Golub LM.

Pharmacol Res. 2011 Feb;63(2):121-9. doi: 10.1016/j.phrs.2010.10.006. Epub 2010 Oct 16. Review.

25.

Introduction and background.

Golub LM.

Pharmacol Res. 2011 Feb;63(2):99-101. doi: 10.1016/j.phrs.2010.10.003. Epub 2010 Oct 16.

PMID:
20937387
26.

Doxycycline effects on serum bone biomarkers in post-menopausal women.

Golub LM, Lee HM, Stoner JA, Reinhardt RA, Sorsa T, Goren AD, Payne JB.

J Dent Res. 2010 Jun;89(6):644-9. doi: 10.1177/0022034510363367. Epub 2010 Mar 26.

27.

Association of gingival crevicular fluid biomarkers during periodontal maintenance with subsequent progressive periodontitis.

Reinhardt RA, Stoner JA, Golub LM, Lee HM, Nummikoski PV, Sorsa T, Payne JB.

J Periodontol. 2010 Feb;81(2):251-9. doi: 10.1902/jop.2009.090374.

28.

Doxycycline [corrected] inhibits mononuclear cell-mediated connective tissue breakdown.

Gu Y, Lee HM, Sorsa T, Simon SR, Golub LM.

FEMS Immunol Med Microbiol. 2010 Mar;58(2):218-25. doi: 10.1111/j.1574-695X.2009.00625.x. Epub 2009 Nov 10. Erratum in: FEMS Immunol Med Microbiol. 2010 Jun 1;59(1):117.

29.

Pilot study: digital subtraction radiography as a tool to assess alveolar bone changes in periodontitis patients under treatment with subantimicrobial doses of doxycycline.

Goren AD, Dunn SM, Wolff M, van der Stelt PF, Colosi DC, Golub LM.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Oct;106(4):e40-5. doi: 10.1016/j.tripleo.2008.06.010. Epub 2008 Aug 20.

PMID:
18718780
30.

Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women.

Golub LM, Lee HM, Stoner JA, Sorsa T, Reinhardt RA, Wolff MS, Ryan ME, Nummikoski PV, Payne JB.

J Periodontol. 2008 Aug;79(8):1409-18. doi: 10.1902/jop.2008.070623 .

31.

Characteristics of collagenase-2 from gingival crevicular fluid and peri-implant sulcular fluid in periodontitis and peri-implantitis patients: pilot study.

Xu L, Yu Z, Lee HM, Wolff MS, Golub LM, Sorsa T, Kuula H.

Acta Odontol Scand. 2008 Aug;66(4):219-24. doi: 10.1080/00016350802183393.

PMID:
18615324
32.

Inhibition of smooth muscle cell proliferation by a chemically modified tetracycline.

Leskinen MJ, Eklund KK, Sorsa T, Golub LM, Kovanen PT, Lindstedt KA.

Coron Artery Dis. 2007 Dec;18(8):663-7.

PMID:
18004118
33.

Inflammatory mediator release following bone grafting in humans: a pilot study.

Preston RD, Meinberg TA, Payne JB, Schmid MJ, Lee HM, Golub LM, Marx DB, Reinhardt RA.

J Clin Periodontol. 2007 Sep;34(9):797-804.

PMID:
17716315
34.

Subantimicrobial dose doxycycline effects on alveolar bone loss in post-menopausal women.

Payne JB, Stoner JA, Nummikoski PV, Reinhardt RA, Goren AD, Wolff MS, Lee HM, Lynch JC, Valente R, Golub LM.

J Clin Periodontol. 2007 Sep;34(9):776-87.

35.

Efficacy of sub-antimicrobial dose doxycycline in post-menopausal women: clinical outcomes.

Reinhardt RA, Stoner JA, Golub LM, Wolff MS, Lee HM, Meinberg TA, Lynch JC, Ryan ME, Sorsa T, Payne JB.

J Clin Periodontol. 2007 Sep;34(9):768-75. Erratum in: J Clin Periodontol. 2007 Dec;34(12):1097. Lee, His-Ming [corrected to Lee, Hsi-Ming].

36.

Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiologic results.

Walker C, Puumala S, Golub LM, Stoner JA, Reinhardt RA, Lee HM, Payne JB.

J Periodontol. 2007 Aug;78(8):1590-601.

37.

Effects of scaling and root planing and sub-antimicrobial dose doxycycline on oral and systemic biomarkers of disease in patients with both chronic periodontitis and coronary artery disease.

Tüter G, Kurtiş B, Serdar M, Aykan T, Okyay K, Yücel A, Toyman U, Pinar S, Cemri M, Cengel A, Walker SG, Golub LM.

J Clin Periodontol. 2007 Aug;34(8):673-81. Epub 2007 Jun 21.

PMID:
17590156
38.

Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation.

Sorsa T, Tjäderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, Golub LM, Brown DL, Mäntylä P.

Ann Med. 2006;38(5):306-21. Review.

PMID:
16938801
39.

Can systemic diseases co-induce (not just exacerbate) periodontitis? A hypothetical "two-hit" model.

Golub LM, Payne JB, Reinhardt RA, Nieman G.

J Dent Res. 2006 Feb;85(2):102-5. No abstract available.

PMID:
16434727
42.

Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines.

Gu Y, Lee HM, Golub LM, Sorsa T, Konttinen YT, Simon SR.

Ann Med. 2005;37(6):450-60.

PMID:
16203617
43.

Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C.

Sandler C, Ekokoski E, Lindstedt KA, Vainio PJ, Finel M, Sorsa T, Kovanen PT, Golub LM, Eklund KK.

Inflamm Res. 2005 Jul;54(7):304-12.

PMID:
16134060
44.

Chemically modified tetracyclines induce apoptosis in cultured mast cells.

Sandler C, Nurmi K, Lindstedt KA, Sorsa T, Golub LM, Kovanen PT, Eklund KK.

Int Immunopharmacol. 2005 Oct;5(11):1611-21.

PMID:
16039551
45.
46.

Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.

Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM.

Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):733-8. Epub 2004 Feb 12.

47.

Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.

Ramamurthy NS, Rifkin BR, Greenwald RA, Xu JW, Liu Y, Turner G, Golub LM, Vernillo AT.

J Periodontol. 2002 Jul;73(7):726-34.

PMID:
12146531
48.

Chemically modified tetracycline (CMT-8) and estrogen promote wound healing in ovariectomized rats: effects on matrix metalloproteinase-2, membrane type 1 matrix metalloproteinase, and laminin-5 gamma2-chain.

Pirilä E, Parikka M, Ramamurthy NS, Maisi P, McClain S, Kucine A, Tervahartiala T, Prikk K, Golub LM, Salo T, Sorsa T.

Wound Repair Regen. 2002 Jan-Feb;10(1):38-51.

PMID:
11983005
49.
50.

A chemically modified tetracycline (CMT-3) is a new antifungal agent.

Liu Y, Ryan ME, Lee HM, Simon S, Tortora G, Lauzon C, Leung MK, Golub LM.

Antimicrob Agents Chemother. 2002 May;46(5):1447-54.

Supplemental Content

Loading ...
Support Center